Benzinga’s Top Ratings Upgrades, Downgrades For July 18, 2023
Upgrades For Carnival Corp (NYSE:CCL), Argus Research upgraded the previous rating of Hold to Buy. For the second…
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived antibody and vaccine from Alzheimer's pipeline.
Why Pardes Biosciences Shares Are Rising Monday
Pardes Biosciences Inc (NASDAQ: PRDS) shares are trading higher Monday after MediPacific agreed to acquire the company.
Benzinga’s Top Ratings Upgrades, Downgrades For April 4, 2023
Upgrades Raymond James upgraded the previous rating for Extra Space Storage Inc (NYSE:EXR) from Outperform to Strong Buy.…
Pardes Biosciences Looks For Alternatives After Failed COVID-19 Study
Pardes Biosciences Inc (NASDAQ:PRDS) reported topline results from its Phase 2 clinical trial evaluating pomotrelvir (previously PBI-0451) for mild-to-moderate COVID-19 in…
12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers Heska (NASDAQ:HSKA) shares increased by 19.9% to $117.0 during Monday’s pre-market session. The company’s market cap stands…
Why American Public Education Shares Are Trading Lower By Around 49%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
ThermoGenesis Holdings, Inc. (NASDAQ: THMO) shares jumped 80% to $3.7820 after the company announced the roll out of ReadyStart cGMP Suites for early-stage cell and gene-therapy companies.
JMP Securities Maintains Market Outperform on Pardes Biosciences, Lowers Price Target to $5
JMP Securities analyst Roy Buchanan maintains Pardes Biosciences (NASDAQ:PRDS) with a Market Outperform and lowers the price target from $9 to $5.
Pardes Biosciences Q4 EPS $(0.41) Beats $(0.50) Estimate
Pardes Biosciences (NASDAQ:PRDS) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.50) by 18 percent. This is a 26.79 percent increase over losses of $(0.56) per share from
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.